Analyst Scoreboard: 6 Ratings For Lexicon Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Lexicon Pharmaceuticals (NASDAQ:LXRX) over the past quarter, with all six analysts maintaining a bullish stance. The average 12-month price target remains at $10.00. Key financial indicators show strong revenue growth but challenges in profitability and asset returns.
August 13, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexicon Pharmaceuticals received six bullish ratings from analysts, maintaining a 12-month price target of $10.00. The company shows strong revenue growth but faces challenges in profitability and asset returns.
The unanimous bullish ratings and consistent price target of $10.00 suggest positive short-term sentiment among analysts. However, the company's financial health shows mixed signals with strong revenue growth but significant profitability challenges.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100